It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The pulmonary metastasis of osteosarcoma (OS) occurs commonly, which resulted from anoikis resistant (AR) of tumor cells as reported by previous studies, but the exact roles of AR in osteosarcoma were not fully studied. Our previous investigations showed fatty acid synthase (FASN) was relating to clinical features of patients with OS. In this study, we aim to explore the functions of FASN in the AR OS cells in vitro and in vivo and study the downstream effectors of FASN. In the present study, we used our established cell model to study the AR. We revealed that AR promoted cell proliferation and migration as determined by colony formation assay and transwell assay. In addition, AR assisted tumor growth in vivo. In the AR cells, the expression of FASN was higher. Thus, we constructed lentiviruses to silence or overexpress FASN in four cell lines to study functions of FASN. Silence of FASN reduced cell colonies and migration while overexpression of FASN increased colonies and migration in suspended cells. Loss of functions of FASN induced cell apoptosis in suspended OS cells while gain of function of FASN suppressed apoptosis as determined by flow cytometry. We found the levels of p-ERK1/2 and Bcl-xL declined when FASN was silenced while they increased when FASN was overexpressed. In addition, results showed that the levels of FASN and its potential related molecules (p-ERK1/2 and Bcl-xL) increased in 143B-AR and MG-63-AR cells. In vivo study showed that inhibition of FASN decreased pulmonary metastasis of OS. In conclusion, we showed that anoikis resistant and FASN as two interactional factors facilitated the progress of osteosarcoma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The First Affiliated Hospital of Nanchang University, Department of Orthopedic Surgery, Nanchang, China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); The University of Hong Kong, Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757)
2 The First Affiliated Hospital of Nanchang University, Department of Orthopedic Surgery, Nanchang, China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073); Jiangxi Cancer Hospital, Division of Chemotherapy, Nanchang, China (GRID:grid.452533.6) (ISNI:0000 0004 1763 3891)
3 The First Affiliated Hospital of Nanchang University, Department of Orthopedic Surgery, Nanchang, China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073)
4 Jiangxi Cancer Hospital, Division of Chemotherapy, Nanchang, China (GRID:grid.452533.6) (ISNI:0000 0004 1763 3891)
5 The University of Hong Kong, Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757)
6 The University of Hong Kong, Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, Hong Kong SAR, China (GRID:grid.194645.b) (ISNI:0000000121742757); Chinese Academy of Science, Shenzhen Institutes of Advanced Technology, Shenzhen, China (GRID:grid.9227.e) (ISNI:0000000119573309)